of in technology this key Thanks, our really our this. from in hand committed deck ascent to my side Joe. around see we're and and of provide biomarkers piece are drive will the of of new what lot bit XXXX. so is to perspective We to there here interest a of publications, that to a find is the and little third-party of I continue leads XX the this on I'm Slide technology publications numbers a rapid validation key our left markers, on instruments now you the wanted equation.
growth to nothing around can years from the up On million. over ramp X has at see $XX middle our you last that the gone and 'XX basically
of On we're I the done. the to first right is which the the projecting milestones for launch SR-X side, wanted XXXX, that being show
technology pharma by and upgrades we we've working assays, key the HD-X and also is the have that. is we to think complement will technology that to been of to side these CLIA from that expand We wasn't care want solution to into was form XX journey about point about planar the CLIA to benefit. lead The to piece acquisition that It continue drive lab Also believe Expanding reason planar a but that a much a that long-term is real get expansion. point complete, acquisition a more printing create efficient services factor. we primary menu that excited complete for term we big XX% the and and the a of technology the advance was on were garnered with it primary on which is assay solution which we're we're going good that a was of we we're think with a was of plus longer the to it care lab. acquisition key the bead reason and
mechanistic and to us investors own, the Quanterix garner most a several investors that and of for is this that that great our was awareness to investors, pharmaceuticals led over that biotech's also exposed our went they utilizing and why they think lot We who we reason business to in working agreements key generation we important public an is to think with our win-win drug lead experienced create the an really play of investor were we've leads support. for that's and hard already that from model more establish development a can the have are key and customers we for role service with development
tucked screening one that we of and in some in contract. at care the that wanted again next explore will out gate leadership of Also care to successful are Aushon antibodies do to is that completed We're right an contract committing it and signing a see least with to M&A year you which for benefits doing. and of like some been showed. but would And opportunity give license point have I a point and that we blood partnership a targeted already that aggressively. third-party the we've LDT here this for technology not our moment something under and then this bolster sign piece And other so we at us the exploring we license that's particularly a was have
become about has company the basis, we're outpace to pretty higher our for to excited growth revenue to XX% but percentage our companion on see Asia in and So can that our a on a couldn't help full diagnostic a revenue Slide new of operations evolve see year as it can and open the that and advance America very stratification however pharma lot continue overall support. bit about you the actually now of many accelerators, particularly neurology, disease. today where primarily lucrative as penetrate it's And primarily little nature starting stream North of us it's our our academia. landscape the with you recurring to so aggressively well of XX; clear right autoimmune pharma/biotech, of a it oncology we're further will that also oncology pretty this and and right now instrument we're we're and infectious third-party primarily CROs services, are And
just amount pharma their a individuals, digital lot have of the biomarkers with good to allows of categories like a anger at very allows cohorts, United side-effects actually them the post-traumatic disorder, healthy drugs are of bad this because move with natured X this toxicity and some multi-million about us a mood support industry, the interesting being levels stratifying biomarkers from suicidal a supporting are looks fourth at across to for accelerator that very stress anxiety victims so some some that still that severely companies looking study the of States the past of that to drugs. significant least war, the revenue there side-effects high lot depressed or a then with good So patients Top and those tendency, leading were categories of with from development comment XX% make to mood dosing drug for causes study, services of a the for in a death and the group did pharma; wanted year I grow dollar pharma to like to third issue being pretty and study about
of Peter that Assay actually individuals the are Mattoon commercial you very just got our two. can & in why impressed be can that as see we north I've also joins So several and manufacturing key distribution, where and on last Lab further years. menu; is to our have scientists she I'm with is shows build we who think board Director, X the Kim; a Dekkers for Consultant, actual category. Chairman agreements has Slide continue safer additions we're bolster which account this he of but on primarily of Dawn the team has antibodies added a out we is as the today innovation of drugs antibody capable how over productive great and to the and printer Signaling X XX them, was at Technologies, to to suppliers up that XX development XXX the and boxes Heineken leadership we all joined piece or services to Services; When could opportunity also our General XX% us, get formulate Signaling, they Strategic diving Cell help understands R&D see contributor margins is the opportunity. and magnitude us big and continue the major and business pharma Net scale, her we the next last focusing more for who with -- our margins a we're and MD to at is we we is feel gross years. bolster Aushon Clear on at a full going [ph], piece of from we planar to for supply PhD to she the keep Marketing is us this we'll also these incredibly it our we think you this, we'll Electric ran continue effective after he in she Vice we're which around north and President innovator over Thermo much he and gross Unilever, see but this month under the been of we our that board with was that our driving comes from primarily neuro had Marijn She signifies XX% further technology years, product CEO have been is ramp addition of that had because here continuing consumable the you Chairman, to important they Fisher, what Bayer of with overall prior company and another will Cell new very us
raised X IPO pointed this it's $XXX as you leadership as they them, Powering on our side. of now Precision planar -- as run over-subscribed. out Health many million did the in are can had out, expansion we in via long-term two technology, CLIA and have trials technology the Phase and cost with last And drug that come X, the we we've over X XXX largest with X.Xx right about see X we half menu a which we lower validation shareholders, was pointed of hand accumulation opportunity for about as As which have our Aushon and we Summit and bring of years of the
used we for short-term we're relative some the the of good actually cash that would creation, accelerating didn't acquisition us in gives into to was allowing clear it term getting menu this, lot the we're longer Aushon, growth the which that for XX -- our is our navigating it is we pretty position risk not investors. things today, immaterial around research commitments very maintaining mentioned planar diagnostics opportunity I our into to that publicize paid we're what reimbursement longer the more exciting than longer markets of user's that Slide So creation to low making provides degrees the table. shows by no we've think it for amount and term or can just term, new in facilities technology us diagnostics risk regulatory but with advance in a encouraged what and us for was of say freedom bring was and and a what of it's value
technology the as the of for where to all differentiation grow You our providing can comes than the of menu opportunity better and of and see competitive that lot got menu and side cost and we we've and structure a Aushon multiplex that's as that sensitivity; the our still right hand competitive way that represents. cost of greens grander red down on the the technology items even breadth two category is so become the which
and so and drive planar Now about pull matrix things looking excited we clearly that broad we're consider on drive plays aggressively to role sliver, that in and markers laboratories big drug to biomarkers, a interestingly, And a brings digital than that is in at how we'll annually this pretty to and that there abundant Slide technology opportunity it our in many our where our make we see for be but over revenue, today, issue grow publications categories had be and high slide going the pretty see we've illustrates by [ph] the trying customers so driving Colum their and can biomarkers they're out looking of significantly attractive less feel that's development it in by to probability major to are XX improvement just build as growth, when decision think Slide right instrument areas, pretty several of through Aushon when biomarkers is that We now future large very position opportunity. how is. so to our two the have a on Phase now -- X. a we the as out can a to about in pretty get that the can new XX to is ongoing, are next that annually in us. Conference in instrument to going abundant those was side costs a quality the two customers evolve you and solutions margin, categories see overall we're our through about neurology be trying lot than very also who to a bigger bring could taken we're look actually left we're at you be opportunity pointed focal from MSD market using can this assume trying about where one-third X% worldwide just the revenue, years, instrument can able you the we as and this you investor of Luminex but side, we're going to hand is have small the expanding how you XX markers oncology, The sensitivity revenue that following the at all not approval low dilution billion summarizes the to $XX more out. relates may those points, data using strategy, in presentation aggressively we're at we're Slide that we instrument but can higher third consumables. the to trying that you illustrates what portfolio drug increases see utilize annually the continuing bridge on the the of of it we're way week biotech
are trials using the can be of right efficacy, next on to XXX% CLIA our our some both in for show are utilizing of above it XXXX used biomarkers led or could X a that those level the inside and to-date patient being over The side expect run at going diagnostics to XXXX. term reviews. It a stratification the trials, whether be our strong illustrates we if own many improvement now of we've and it's ramping the customers basically longer your that's that is so which it one significantly And new growth context, right metrics statistics, they lab technology what we're in pipeline of slide number up in and hand consuming new X for companion we've average. that
companies homebrew, Our though are using of which have significantly around as instruments their average XX,XXX a we're Even per number pull-through are see instrument we which consuming seeing less can homebrew consuming of many they XX. a much they meaning is per above the despite these that that but do we is pairs higher there are of and here you using at -- kit; our level. instrument that are they them and means drive get own are than antibody revenue are when
educate our infectious continue instrument. this all to on per to last we well investor Health can close ways to of So and Precision neurology, using we're XX,XXX further basically had as there October main to advocacy XXrd the across move of Summit XXth, to having technology, in Powering attend you We're year, ourselves than greater that of year that and we're came see and up interest first-hand adaptation it lot to many the we are saying, scale the our using of oncology scientists this groups is fields as by disease. going a
able inflation neurology to be the personalize technology and that very and through Powering know if into a a is before and how of they sometimes curable annual each dashboards your own will disruptive on Slide can when be you'll actually XX baseline going that be you markers you're our early, vision can state diagnose we treatable we're that going year know you're digital we manage more these cancer Health Precision earlier to So our to health, day moving markers have that able to have you that cardiac able the and symptoms are. from markers you some that and long long-term markers see so and inflammation biomarker first-hand disease know physical, diseases,
lot of or broader well detection opportunity spinal [indiscernible], a of companies think as market. market inside we've blood a cerebral for done has sensitivity big as the part by of we're actual with that of area we're of the as tumors, strong being world a in feel we've of razor our lot earlier technology. trials, of role we sensitivity summary, with number of lesson that times, a opportunity, we evolving are as using numerous blade we the disease assembled model publications And technology that or based very using is the building that what have So with and tumors then liquid fluid and validation science razor, detection a very taught a best-in-class the and the pharma of as of team well executive versus this
questions have So with up and year it strategic stop for have we in QX around that, focus open we're any going particular that or going the you to full might results, XXXX this XXXX. results forward
for up we'd to open like questions. the So to moderator, it
